



## Computer and Technology Supported Development of Vaccines 2.0

Guest Editors:

**Dr. Pedro A. Reche**

Laboratory of Immunomedicine,  
Department of Immunology &  
O2, School of Medicine,  
Complutense University of  
Madrid, Pza Ramon y Cajal, S/N,  
28040 Madrid, Spain

**Prof. Dr. Francesco  
Pappalardo**

Department of Drug Sciences,  
University of Catania, 95125  
Catania, Italy

Deadline for manuscript  
submissions:

**closed (30 November 2023)**

### Message from the Guest Editors

The ongoing COVID-19 pandemic has underscored our current ability to develop vaccines quickly. The main aim of this Special Issue is to put forward new knowledge, concepts, and technologies that can be recruited to facilitate vaccine design, including contributions from proteomics, immunology, structural biology, systems biology, and mathematical modeling. In this context, the adoption of modeling and simulation for the development and de-risking of vaccines will be the key to drastically reducing animal and human testing, lowering costs, and shortening marketing times.

We particularly welcome research articles and reviews on complete-genome sequencing of pathogens, computational, high-throughput technologies for antigen and epitope discovery, antigen receptor profiling, the modeling of antigen–antigen receptor interactions, and the computational simulation of immune responses. Likewise, contributions utilizing these technologies to develop vaccines and immunotherapeutics to treat cancer, allergies, and autoimmune diseases are also welcome.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)